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We reported previously that exogenously added hu-
man group V phospholipase A2 (hVPLA2) could elicit
leukotriene B4 (LTB4) biosynthesis in human neutro-
phils (Han, S. K., Kim, K. P., Koduri, R., Bittova, L.,
Munoz, N. M., Leff, A. R., Wilton, D. C., Gelb, M. H., and
Cho, W. (1999) J. Biol. Chem. 274, 11881–11888). To deter-
mine the mechanism of the hVPLA2-induced LTB4 bio-
synthesis in neutrophils, we thoroughly examined the
effects of hVPLA2 and their lipid products on the activ-
ity of group IVA cytosolic PLA2 (cPLA2) and LTB4 bio-
synthesis under different conditions. As low as 1 nM
exogenous hVPLA2 was able to induce the release of
arachidonic acid (AA) and LTB4. Typically, AA and LTB4
were released in two phases, which were synchronized
with a rise in intracellular calcium concentration
([Ca2]i) near the perinuclear region and cPLA2 phos-
phorylation. A cellular PLA2 assay showed that hVPLA2
acted primarily on the outer plasma membrane, liberat-
ing fatty acids and lysophosphatidylcholine (lyso-PC),
whereas cPLA2 acted on the perinuclear membrane.
Lyso-PC and polyunsaturated fatty acids including AA
activated cPLA2 and 5-lipoxygenase by increasing
[Ca2]i and inducing cPLA2 phosphorylation, which
then led to LTB4 biosynthesis. The delayed phase was
triggered by the binding of secreted LTB4 to the cell
surface LTB4 receptor, which resulted in a rise in [Ca
2]i
and cPLA2 phosphorylation through the activation of
mitogen-activated protein kinase, extracellular signal-
regulated kinase 1/2. These results indicate that a main
role of exogenous hVPLA2 in neutrophil activation and
LTB4 biosynthesis is to activate cPLA2 and 5-lipoxygen-
ase primarily by liberating from the outer plasma mem-
brane lyso-PC that induces [Ca2]i increase and cPLA2
phosphorylation and that hVPLA2-induced LTB4 pro-
duction is augmented by the positive feedback activa-
tion of cPLA2 by LTB4.
Phospholipase A2 (PLA2)
1catalyzes the release from the sn-2
position of certain membrane phospholipids of arachidonic acid
(AA) that can be transformed into potent inflammatory lipid
mediators, including prostaglandins, leukotrienes, and throm-
boxanes. Multiple forms of mammalian PLA2 have been iden-
tified from mammalian tissues, which include several forms of
secretory PLA2 (sPLA2) (1), group IVA Ca
2-dependent cytoso-
lic PLA2 (cPLA2) (2), and group VI Ca
2-independent PLA2
(iPLA2) (3). Recent studies have indicated that sPLA2s work in
concert with cPLA2 to induce eicosanoid formation in different
cells (4–6). Neutrophils are inflammatory cells that release AA
and 5-lipoxygenase products, most notably leukotriene B4
(LTB4), upon activation by various agonists, including a bacte-
rial peptide, formyl-Met-Leu-Phe (fMLP). It was reported that
human neutrophils contain several forms of endogenous
PLA2s, including cPLA2, iPLA2, and group V and group X
sPLA2s (7). However, roles of these PLA2s in inflammatory
actions of neutrophils, biosynthesis and release of LTB4 in
particular, have not been elucidated fully. Based on the effects
of exogenously added sPLA2, AA, and 5-lipoxygenase (5-LO)
products on cPLA2 activity, it was postulated earlier that stim-
ulus-induced AA release or exocytosis of sPLA2 activates cPLA2
by initiating the formation of LTB4 which leads to the phos-
phorylation of cPLA2 (8). Similarly, both sPLA2 and cPLA2
were shown to be involved in the fMLP-stimulated AA release
from human neutrophils (9). Recently, however, it was reported
that fMLP-induced secretion of group V sPLA2 from human
neutrophils did not lead to LTB4 biosynthesis (7). Instead,
cPLA2 was reported to be entirely responsible for the fMLP-
stimulated LTB4 release from human neutrophils (7). Inde-
pendently, we showed that exogenously added human group V
PLA2 (hVPLA2) could induce AA and LTB4 release from
unprimed human neutrophils half as effectively as fMLP (10)
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and that hVPLA2 bound to cell surface heparan sulfate proteo-
glycans was eventually internalized and degraded (11). To un-
derstand better the interplay between sPLA2 and cPLA2 in
leukotriene biosynthesis in neutrophils, we thoroughly exam-
ined the effects of sPLA2s and their lipid products on cPLA2
activity and leukotriene biosynthesis under different condi-
tions. Results not only account for the discrepancy in previous
reports but also provide new insights into the mechanism by
which sPLA2 and cPLA2 work in concert to achieve effective
and controlled leukotriene biosynthesis in neutrophils.
EXPERIMENTAL PROCEDURES
Materials—Arachidonyltrifluoromethyl ketone (AACOCF3) was pur-
chased from Biomol (Plymouth Meeting, PA). Surfactin was a generous
gift from Dr. C. H. Lee of CheilJedang Co. (Incheon, Korea). The p38
mitogen-activated (MAP) kinase inhibitor SB203580 was purchased
from Upstate Biotechnology (Lake Placid, NY). Anti-cPLA2 monoclonal
antibody was generously provided by Dr. James Clark of the Genetics
Institute (Cambridge, MA). [3H]AA and 14C-labeled oleic acid (OA) were
purchased from American Radiochemical Co. (St. Louis, MO). 1-Stear-
oyl-2-[14C]arachidonoyl-sn-glycero-3-phosphatidylcholine ([14C]SAPC),
goat anti-rabbit immunoglobin conjugated with horseradish peroxidase,
goat anti-mouse immunoglobin conjugated with horseradish peroxi-
dase, enhanced chemiluminescence and molecular weight markers
were purchased from Amersham Biosciences. Anti-Activ™-extracellu-
lar signal-regulated kinase (ERK)1/2 antibody, Anti-Active™-p38 MAP
kinase antibody, and a mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase (MEK) inhibitor, U0126, were pur-
chased from Promega Co. LTB4, LTB4 dimethyl amide (LTB4DMA) and
iPLA2 inhibitor (E)-6-(bromoethylene)tetrahydro-3-(1-naphthalenyl)-
2H-pyran-2-one (bromoenol lactone) were from Cayman Chemical Co.
(Ann Arbor, MI). N-((6-(2,4-dinitrophenyl)amino)hexanoyl)-2-(4,4-dif-
luoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexa-
decanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt
(PED6), Fluo-4 AM and 1,1-didodecyl-3,3,3,3-tetramethylindocarbo-
cyanine perchlorate (DiIC12) were purchased from Molecular probes
(Eugene, OR). 1-Palmitoyl-2-hydroxyl-sn-glycero-3-phosphocholine
(lyso-PC) was purchased from Avanti Polar Lipids (Alabaster, AL). AA
and ionomycin were purchased from Sigma.
Expression and Purification of sPLA2—Recombinant human group
IIa PLA2 (hIIaPLA2) was prepared as described (12). Recombinant
hVPLA2 and mutants were expressed in Escherichia coli, refolded, and
purified as described previously (10, 13). The purity of enzymes as-
sessed by SDS-PAGE was consistently higher than 90%.
Isolation of Human Neutrophils—Human neutrophils were prepared
from heparinized venous blood collected from healthy medication-free
donors by dextran sedimentation, followed by isolymph centrifugation
and removal of remaining red blood cells by hypotonic lysis (14). The
resultant cell population consisted of 95% neutrophils with 98%
viability as judged by trypan blue exclusion.
Fatty Acid and LTB4 Release from Human Neutrophils—Dual radio-
labeling of neutrophils was achieved by incubating 107 cells with
[3H]AA and [14C]OA (0.1 Ci/ml each) in calcium-free Hanks’ balanced
salt solution (HBSS) for 3 h. [3H]AA and [14C]OA that had not been
incorporated into cellular lipids were removed by washing the cells
three times with HBSS containing 0.2% bovine serum albumin (BSA).
Radiolabeled cells (106) were resuspended in 160 l of HBSS containing
1.2 mM CaCl2 and 0.2% BSA, preincubated with a selected inhibitor for
20 min at 37 °C if necessary, and then were stimulated with hVPLA2.
The reaction was quenched by centrifugation, and the radioactivity in
the cell pellet and the medium was measured separately by a two-
channel liquid scintillation counter. LTB4 levels were determined using
a LTB4 enzyme immunoassay kit from Cayman and then corrected for
background signals from control cells that were not treated with
hVPLA2.
Measurement of cPLA2 Activity—Neutrophils (2  10
6 cells) were
stimulated with varying concentrations of hVPLA2. The reaction was
quenched by adding 1 ml of ice-cold water, and the reaction mixture was
centrifuged. The pellet was resuspended in 70 l of lysis buffer (20 mM
Tris-HCl, pH 8.0, containing 2.5 mM EDTA, 10 g/ml leupeptin, 5 g/ml
aprotinin, 1 mM phenylmethylsulfonyl fluoride, 2 mM VO4, 50 mM NaF,
and 5 g/ml pepstatin) and sonicated briefly. The resulting cell lysate
was pretreated with 10 l of dithiothreitol (final concentration 10 mM)
on ice for 5 min to inactivate sPLA2, and 10 l of 1 mM CaCl2 (final
concentration 0.1 mM) was then added to each sample. The cPLA2
substrate solution was prepared by drying a chloroform solution of
[14C]SAPC under a stream of N2 and suspending the film in 100 l of
10% aqueous ethanol by vortexing. The reaction was initiated by adding
a 10 l-portion of the substrate solution (final concentration 9 M) to
each cell lysate. The reaction was carried out for 30 min at 37 °C and
was quenched by adding 560 l of Dole’s reagent (heptane, 2-propanol,
1 N H2SO4, 400:390:10 (v/v)), followed by 110 l of H2O, vortexed for
20 s, and then centrifuged at 13,000  g. The 180-l upper layer was
transferred to 800 l of hexane containing 25 mg of silica gel. The
800-l samples was then mixed with 2 ml of scintillation fluids, and the
radioactivity was counted in a liquid scintillation counter.
Immunoblotting—Aliquots of neutrophils (2 106 cells/sample) were
centrifuged at 13,000  g for 20 s, and cell pellets were lysed by the
addition of the ice-cold lysis buffer (20 mM Tris-HCl, pH 8.0, containing
5 mM EDTA, 40 mM NaCl, 30 mM Na4P2O7, 10 g/ml leupeptin, 5 g/ml
aprotinin, 5 g/ml chymostatin, 2 mM diisopropylfluorophosphate, 1 mM
phenylmethylsulfonyl fluoride, 2 mM Na3VO4, 50 mM NaF, and 5 g/ml
pepstatin, 1% Nonidet P-40, and 0.5% deoxycholic acid). After 20 min on
ice, the samples were centrifuged (13,000  g, 10 min) to remove
nuclear and cellular debris. Supernatants were mixed with the gel
loading buffer (0.125 M Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% SDS,
0.005% bromphenol blue), and boiled for 5 min. Equivalent amounts of
protein (50 g) were loaded onto SDS-polyacrylamide gels (10% of
cPLA2 and 12% for p38 and ERK1/2 MAP kinases). Electrotransfer
of protein from the gel to the polyvinylidene difluoride membrane was
achieved using a semidry system (400 mA, 60 min). The membrane was
blocked with 1% BSA for 60 min, then incubated with primary antibod-
ies (anti-cPLA2, Anti-Active™-ERK1/2, or Anti-Active™-p38 antibody).
Measurement of [Ca2]i—Measurement of intracellular calcium con-
centration ([Ca2]i) was performed with a Zeiss LSM 510 laser scanning
confocal microscope using Fluo-4 AM as the indicator. Neutrophils (107
cells/ml) were incubated in HBSS containing 1.2 mM Ca2, 1% BSA, and
2 M Fluo-4 for 30 min at 37 °C. Labeled cells were seeded into each of
eight wells on a sterile Nunc Lak-TeKII™ chambered cover glass filled
with 400 l of HBSS containing 1.2 mM Ca2, and incubated at 37 °C
with 5% CO2 for 10 min. After washing once with HBSS containing 1.2
mM Ca2, 10 nM hVPLA2 (or 3 M lyso-PC, 3 M AA, 0.3 M LTB4) was
added, and the fluorescence intensity of Fluo-4 was monitored with a
488 nm argon/krypton laser and a 530 nm linepass filter. A 63 (1.2
numerical aperture) water immersion objective was used for all exper-
iments. Images were analyzed using the analysis tools provided in the
Zeiss biophysical software package. [Ca2]i was calibrated as described
previously using the reported calcium dissociation constant value (i.e.
345 nM) of Fluo-4 (15).
Confocal Microscopy Imaging of PLA2 Activity—Neutrophils (10
6
cells/ml) were seeded into each of eight wells on a sterile Nunc Lak-
TeKII™ chambered cover glass filled with 400 l of HBSS and incu-
bated at 37 °C with 5% CO2 for 10 min. After the cells were washed once
with HBSS, they were overlaid with 10 l of PED6 vesicle solution (0.75
mM POPS/cholesterol/POPG/PED6/DiIC12 (107:31:20:1:1 in a mol ra-
tio) mixed vesicles in HBSS) and incubated for 50 min at 37 °C with 5%
CO2. After rinsing the labeled cells six times with HBSS containing 1.2
mM Ca2, 10 nM hVPLA2 was added to cells. Imaging was done with a
Zeiss LSM 510 laser scanning confocal microscope with the detector
gain adjusted to eliminate the background autofluorescence. The fluo-
rescence resonance energy transfer (FRET) from the BODIPY™ group
of the hydrolyzed PED6 to DiIC12 was monitored with a 488 nm
argon/krypton laser and a 585 nm linepass filter. A 63 (1.2 numerical
aperture) water immersion objective was used for all experiments.
Leukotriene Analysis by HPLC-Electrospray Ionization-Mass Spec-
trometry—The analysis of leukotriene composition secreted to the
growth medium was performed as reported previously (16, 17). After
neutrophils (108 cells) were incubated with 1 or 10 nM hVPLA2, they
were treated with 2 volumes of ice-cold methanol containing 5 ng of
internal standard, prostaglandin B2 (PGB2). The samples were diluted
with water to a final methanol concentration lower than 20%, and
extraction was quickly carried out using a Supelclean LC-18 solid phase
cartridge (Supelco, Bellafonte, PA). The retained material was eluted
using 90% aqueous methanol. After evaporation of solvent, the dried
extract was solubilized in 100 l of solvent A (methanol/acetonitrile/
water/acetic acid, 10:10:80:0.02, v/v/v/v, pH 5.5, adjusted with ammo-
nium hydroxide), injected into a C18 reverse phase HPLC column (5 
150 mm; Waters, Milford, MA) that was interfaced directly with the
electrospray source of a triple quadrupole mass spectrometer (Micro-
mass Qurattro II). The column was eluted with a linear gradient of
solvent B (acetonitrile/methanol, 65:35) from 40 to 100% at a flow rate
of 100 l/min over 30 min. Each leukotriene peak was analyzed by mass
spectrometry measuring the ion abundance for the following collision-
induced transformation at the corresponding retention times: LTB4 and
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6-trans-LTB4 isomers (m/z 335 3 195), 20-hydroxy-LTB4 (m/z 351 3
195), 20-carboxy-LTB4 (m/z 365 3 195). Quantitation of individual
peaks was carried out using their mass ion abundance relative to that
of PGB2.
RESULTS
hVPLA2-induced Fatty Acid and LTB4 Release from Neutro-
phils—We showed previously that exogenously added hVPLA2
triggers AA release and LTB4 secretion from unprimed human
neutrophils (10). To understand better the mechanism of
hVPLA2-induced LTB4 biosynthesis, we carefully examined the
time course of the fatty acid and LTB4 release from neutrophils
in the presence of varying concentrations of exogenously added
hVPLA2. First, we measured the hVPLA2 concentration de-
pendence of fatty acid release from neutrophils double labeled
with [3H]AA and [14C]OA. Because of the high AA specificity of
cPLA2 and lack of fatty acid selectivity of sPLA2s, the [
3H]AA
release in this system would reflect both sPLA2 and cPLA2
activities, whereas the [14C]OA release would largely represent
sPLA2 activity. As illustrated in Fig. 1A, the [
3H]AA release
was detected at a lower hVPLA2 concentration than was
[14C]OA release. For instance, at 1 nM hVPLA2 the [
3H]AA
release was twice larger than the control, whereas the [14C]OA
release was essentially the same as the control. At 100 nM
hVPLA2, however, both [
3H]AA and [14C]OA releases were
about three times higher than the control. This suggests that at
lower concentrations of exogenously added hVPLA2, cPLA2 is
mainly responsible for the AA release, whereas at higher con-
centrations (i.e.10 nM) hVPLA2 also contributes to the overall
AA release. Although it is difficult to monitor the secretion of
endogenous hVPLA2 in response to the exogenously added
hVPLA2, the contribution of the former to the AA release
should be insignificant under our experimental conditions.
This is because at lower concentrations of exogenously added
hVPLA2, cPLA2 plays a predominant role in overall AA release,
whereas at higher concentrations (i.e. 10 nM) of exogenously
added hVPLA2, the amount of secreted endogenous hVPLA2
(1.5 nM) (7) should be much smaller than that of exogenous
hVPLA2. As reported previously (10, 11), hIIaPLA2 up to 100
nM had little effect on fatty acid release under the same condi-
tions, underscoring the unique ability of hVPLA2 to release
fatty acid from unprimed neutrophils. We then measured the
LTB4 release from neutrophils as a function of hVPLA2 con-
centration (Fig. 1B). Unlike the AA release that occurred with
as low as 1 nM exogenously added hVPLA2, the LTB4 release
was not detectable at 1 nM hVPLA2. However, the LTB4 release
was clearly seen with 10 nM hVPLA2. As reported earlier (10,
11), 100 nM hVPLA2 was about half as effective as 1 M fMLP
 5 g/ml cytochalasin B in inducing the LTB4 release. As a
negative control, hIIaPLA2 up to 100 nM was shown to have
little effect on LTB4 release. Together, these data suggest that
the release of AA and LTB4 biosynthesis in human neutrophils
have disparate dependence on hVPLA2 concentration acting on
their cell surfaces.
We then monitored the kinetics of fatty acid release from
dual labeled neutrophils by 10 nM hVPLA2. As shown in Fig.
2A, the [14C]OA release showed simple saturation kinetics,
whereas the [3H]AA release exhibited more complex two-phase
kinetics under the same conditions, suggesting that at least
two distinct pathways are involved in the latter case. The early
phase of [3H]AA release reached a plateau in 10–20 min, as
was the case with the [14C]OA release; however, the delayed
phase of [3H]AA release followed after 20 min and extended
for about 1 h. When neutrophils were incubated with a cPLA2
inhibitor, AACOCF3 (25 M) (18) or surfactin (10 M) (19), prior
to the addition of hVPLA2, the delayed phase AA release was
abrogated, whereas the early phase AA release was modestly
(about 30%) reduced. On the other hand, OA release remained
essentially unchanged after treatment with cPLA2 inhibitors.
An iPLA2 inhibitor, bromoenol lactone (10 M) had little effect
on the time course of fatty acid release (data not shown). In
conjunction with the data shown in Fig. 1, these data suggest
that in the presence of 10 nM exogenous hVPLA2, both hVPLA2
and cPLA2 are involved in the early phase of [
3H]AA release,
whereas cPLA2 is primarily responsible for the delayed phase
of [3H]AA release. The involvement of hVPLA2 only in the early
phase of AA release is also consistent with our previous finding
that the exogenously added hVPLA2 is internalized and de-
graded in neutrophils within the first 10 min under similar
experimental conditions (11).
We also monitored the time course of LTB4 release by 1–100
nM exogenous hVPLA2 under the same experimental conditions
(Fig. 2B). With 10 nM hVPLA2, the LTB4 release reached a
saturation in 5–10 min, consistent with the early phase AA
release curve, and started to decline until it increased again at
15–20 min, which is approximately synchronized with the de-
layed phase AA release. The delayed phase LTB4 release was
FIG. 1. Dependence of fatty acid and LTB4 release on hVPLA2 concentration. A, human neutrophils were labeled for 3 h with [
3H]AA and
[14C]OA and incubated for 20 min at 37 °C with different concentrations (1–100 nM) of hVPLA2 or hIIaPLA2 in HBSS containing 1.2 mM Ca
2 and
0.2% BSA. Black and white bars indicate [3H]AA and [14C]OA release, respectively, by hVPLA2. Gray bars indicate [
3H]AA release by hIIaPLA2.
B, human neutrophils were incubated for 30 min at 37 °C with different concentrations (1–100 nM) of hIIaPLA2 or hVPLA2 in HBSS containing
1.2 mM Ca2. The supernatants were collected, and the LTB4 level was assayed as described under “Experimental Procedures.” Black and white
bars indicate LTB4 secretion by hVPLA2 and hIIaPLA2, respectively. Data represent the mean  S.E. from triplicate measurements.
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much more pronounced with 100 nM hVPLA2. Importantly,
treatment of neutrophils with AACOCF3 abrogated the LTB4
release, indicating that cPLA2 is mainly responsible for LTB4
biosynthesis under these conditions. With 1 nM hVPLA2, the
LTB4 release rapidly reached a maximal point at 5 min and
then decreased to a basal level after 10 min, which is consistent
with the lack of LTB4 release at 10 min shown in Fig. 1B. These
data indicate, however, that as low as 1 nM exogenous hVPLA2
can stimulate the LTB4 biosynthesis.
In neutrophils AA is transformed into several different 5-LO
products including LTB4 (16). Also, LTB4 is known to be de-
graded and inactivated by microsomal -oxidation and peroxi-
somal -oxidation in myeloid cells (16). To understand better
the fate of AA liberated in neutrophils, we analyzed the com-
position of lipid products that neutrophils released to the me-
dium when they were challenged with 1 and 10 nM exogenous
hVPLA2, respectively. The chromatogram in Fig. 3A shows that
at 1 nM hVPLA2 two main leukotriene products are 20-carboxy-
LTB4 and 20-hydroxy-LTB4, which are produced as a conse-
quence of LTB4 oxidation (16). These data thus confirm that
even 1 nM exogenous hVPLA2 can induce the biosynthesis of a
considerable amount of LTB4. It appears, however, that LTB4
is degraded relatively rapidly to oxidation products that do not
cross-react with the LTB4 antibody used in the commercial
LTB4 detection kit, hence there is no LTB4 signal with 1 nM
hVPLA2 in Fig. 1B. With 10 nM hVPLA2, LTB4 was clearly seen
along with other leukotrienes. As was the case with 1 nM
hVPLA2, 20-carboxy-LTB4 was the most abundant component.
hVPLA2-induced Activation of cPLA2 in Neutrophils—Accu-
mulating evidence has indicated that cPLA2 plays a pivotal role
in the receptor-mediated mobilization of AA and eicosanoid
biosynthesis in neutrophils (7, 9, 20). Furthermore, several
reports have indicated that exogenously added sPLA2s activate
cPLA2 in neutrophils (8) and other mammalian cells (21, 22).
Also, the occurrence of the delayed phase AA release in our
studies implies that cPLA2 is activated during or after the early
phase of AA release. We therefore measured the effect of
hVPLA2 on cPLA2 activities in neutrophils. It has been estab-
lished that cPLA2 can be activated by a rise in [Ca
2]i (23) and
the phosphorylation of Ser residues, most notably Ser505 (24).
In neutrophils, it was shown previously that exogenously
added pancreatic sPLA2 phosphorylated and activated cPLA2
through the formation of 5-LO products, including LTB4 (8). To
elucidate the mechanism by which hVPLA2 activates cPLA2,
we monitored the time-dependent changes in cPLA2 activity
and the phosphorylation by enzyme assay and electrophoretic
mobility assay, respectively, upon incubating neutrophils with
10 nM hVPLA2. First, we measured the time course of cPLA2
activity from neutrophil lysates. To eliminate residual sPLA2
activities in the cell lysates, the lysates were incubated with 10
mM dithiothreitol before the addition of a cPLA2 substrate,
[14C]SAPC. As shown in Fig. 4A, the cPLA2 activity of neutro-
phils was enhanced by exogenously added hVPLA2, but the
time course of activation was rather complex. The cPLA2 ac-
tivity increased about 2.3-fold in first 5 min but then started to
decrease until it rose again at 10 min and reached a plateau
in 20 min. As was the case with AA and LTB4 release, it thus
appears that cPLA2 activation also occurs in two phases.
Interestingly, preincubation of neutrophils with a LTB4 re-
ceptor antagonist, LTB4DMA (0.3 M) abrogated the delayed
phase activation of cPLA2, suggesting that it is mediated
through the binding of LTB4 to its cell surface receptor.
Because the cPLA2 assay of the lysates was done in the
presence of a saturating concentration of calcium for cPLA2
(0.1 mM), the activity enhancement should reflect mainly the
protein phosphorylation. Indeed, Fig. 4B shows that the ex-
tent of cPLA2 phosphorylation is synchronized with the
change in cPLA2 activity shown in Fig. 4A.
We then measured the effect of exogenously added hVPLA2
on [Ca2]i. We monitored the fluctuation of [Ca
2]i with a
fluorescence indicator, Fluo-4. Although UV-excitable Ca2 in-
dicators, such as Indo-1 and Fura-2, allow more accurate
[Ca2]i measurement by a ratiometric analysis, we used Fluo-4
in our studies because the UV irradiation severely damages
human neutrophils. We monitored the fluorescence intensity
changes of Fluo-4 in the perinuclear region by confocal micros-
copy. As shown in Fig. 5, the addition of 10 nM hVPLA2 evoked
an immediate increase in [Ca2]i (to 500 nM) in the perinu-
clear region. Interestingly, a second [Ca2]i spike was seen in
the perinuclear region, which was about 50% of the first one in
magnitude. The timing of the second spike varied between 10
and 15 min among different cells. As seen with the progress
curve of cPLA2 activation (see Fig. 4A), the second [Ca
2]i peak
was completely abrogated when the cells were pretreated with
a LTB4 receptor antagonist, LTB4DMA. In conjunction with
cPLA2 phosphorylation data, these data suggest that the addi-
FIG. 2. Time courses of hVPLA2-induced fatty acid and LTB4 release from neutrophils. A, dual radiolabeled neutrophils were incubated
with 10 nM hVPLA2, and the time courses of [
3H]AA (E) and [14C]OA (‚) releases were monitored. Also, the [3H]AA release was monitored for
neutrophils preincubated for 30 min with 25 M AACOCF3 before the addition of 10 nM hVPLA2 (). B, time courses of LTB4 secretion were
measured in the presence of 1 nM (‚), 10 nM (E), and 100 nM () hVPLA2. Also, the LTB4 release from neutrophils preincubated for 30 min with
25 M AACOCF3 before the addition of 10 nM hVPLA2 was measured (). Data represent the mean  S.E. from triplicate measurements.
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tion of hVPLA2 activates cPLA2 by increasing the [Ca
2]i and
inducing cPLA2 phosphorylation in both the early and the
delayed phases and that the delayed phase activation is medi-
ated through the binding of LTB4 to its cell surface receptor.
Sites of hVPLA2 and cPLA2 Actions in Neutrophils—To de-
termine the exact site of actions for hVPLA2 and cPLA2 in
neutrophils, we performed a cellular PLA2 activity assay using
a fluorescent phospholipid, PED6. We recently reported the use
of PED6 in the real time activity assay for hVPLA2 internalized
into human embryonic kidney 293 cells (25). Because cPLA2
has much lower specific activity than sPLA2 for this phospho-
lipid (25, 26), the cellular cPLA2 activity would yield only a low
fluorescence signal from PED6 hydrolysis. To improve the sen-
sitivity of assay for cPLA2, we double labeled neutrophil mem-
branes with DiIC12 and PED6. DiIC12 is a nonhydrolyzable
fluorescent lipid that shows a greatly enhanced fluorescent
intensity at 585 nM by FRET from hydrolyzed PED6. Indeed,
the in vitro FRET assay using POPS/cholesterol/POPG/PED6/
DiIC12 (107:31:20:1:1) vesicles yielded a three times larger
fluorescence change than the assay using POPS/cholesterol/
POPG/PED6 (107:31:20:1) vesicles in the presence of the same
concentration of cPLA2 (10 nM) (data not shown). When neu-
trophils double labeled with DiIC12 and PED6 were incubated
with 10 nM exogenous hVPLA2, prominent signals appeared at
the plasma membrane and the perinuclear region after 5 min
(Fig. 6). Because of the high laser power necessary for visual-
ization of the signal change, real time monitoring was not
attempted in this case because it would lead to serious photo-
bleaching. Most importantly, the perinuclear signal was abro-
gated when the labeled neutrophils were pretreated with 25 M
AACOCF3 before the addition of hVPLA2. No change was ob-
served, however, when the cells were treated with 10 M bro-
moenol lactone. This clearly indicates that the perinuclear
signal is the result of cPLA2 activity and that hVPLA2 primar-
ily acts on the plasma membrane in neutrophils. Taken to-
gether, these results indicate that hVPLA2-induced activation
of cPLA2 by calcium increase and phosphorylation results in
the lipolytic action of cPLA2 in the perinuclear region.
Effects of hVPLA2 Products and LTB4 on cPLA2 Activity—To
determine the mechanism by which hVPLA2 activates cPLA2,
we first measured the effect of exogenously added lipid prod-
ucts of hVPLA2, fatty acids (AA and OA) and lysophospholipids
(lyso-PC) on the [3H]AA and LTB4 release from neutrophils.
Lyso-PC was selected as a representative lysophospholipid be-
cause the main phospholipid component of the outer plasma
membrane of mammalian cells is phosphatidylcholine. As illus-
trated in Fig. 7A, 3 M lyso-PC had the same potency as 10 nM
hVPLA2 in eliciting [
3H]AA release from labeled neutrophils.
Even 1 M lyso-PC was able to induce significant [3H]AA re-
lease (data not shown). Although less potent than lyso-PC, AA
was also able to induce [3H]AA release. In this case, 10 M
exogenous AA was as effective as 10 nM hVPLA2. In contrast,
OA up to 30 M showed negligible effects on [3H]AA release.
Lyso-PC and AA showed an additive effect when used in com-
bination. A similar trend was seen with the LTB4 release.
Lyso-PC (3 M) was nearly twice as effective as 10 nM hVPLA2
in net LTB4 release activity (see Fig. 7B), whereas the same
concentration of AA was about 30% active. OA up to 30 M
FIG. 3. HPLC-MS analysis of LTB4 derivatives secreted from human neutrophils. Representative chromatograms are shown for
neutrophils treated with 1 nM (A) and 10 nM (B) hVPLA2. Extracts of growth medium dissolved in 10:10:80:0.02 methanol/acetonitrile/water/acetic
acid (pH 5.5) with the internal standard PGB2 were injected into a C18 reverse phase HPLC column (5  150 mm) that was directly interfaced
with the electrospray source of a triple quadrupole mass spectrometer. The column was eluted using a linear gradient of acetonitrile/methanol
(65:35) from 40 to 100%. Quantitation of individual peaks was carried out using their mass ion abundance relative to that of PGB2.
FIG. 4. Time-dependent activation
of neutrophil cPLA2 by exogenous
hVPLA2. A, neutrophils (2  10
6 cells)
suspended in 200 l of HBSS containing
1.2 mM CaCl2 were incubated with 10 nM
hVPLA2 in the absence () or presence
(E) of 0.3 M LTB4DMA for a given period
and were pelleted and lysed. The cPLA2
activity of the cell lysate was measured
using [14C]SAPC as substrate in the pres-
ence of 10 mM dithiothreitol and 0.1 mM
CaCl2. Data represent the mean  S.E.
from triplicate measurements. B, immu-
noblotting of the cell lysates using an an-
ti-cPLA2 antibody after incubation with
10 nM hVPLA2 for different periods.
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failed to induce LTB4 release. Given that AA constitutes only a
small fraction (5%) of fatty acids incorporated into the phos-
pholipids in the outer plasma membrane, these data indicate
that the cellular effect of hVPLA2 is mediated largely through
the formation of lyso-PC.
Interestingly, the exogenous addition of 0.3 M LTB4 en-
hanced the [3H]AA release as much as 10 nM hVPLA2 (Fig. 7A).
Furthermore, preincubation of labeled neutrophils with 0.3 M
LTB4DMA significantly reduced the positive effects of hVPLA2,
lyso-PC, and AA on [3H]AA release, suggesting that a large
part of their effects is mediated through the activation of LTB4
receptors on the neutrophil surfaces. To investigate this aspect
further, we measured the time course of cPLA2 activation by
lyso-PC in the presence and absence of LTB4DMA. As described
above, the cPLA2 activity assay of the lysates was performed in
the presence of 0.1 mM calcium and 10 mM dithiothreitol, and
the activity enhancement should mainly reflect cPLA2 phos-
phorylation. Fig. 8 shows that lyso-PC increased the cPLA2
activity (and phosphorylation) in two phases, which is reminis-
cent of two-phase cPLA2 activation and phosphorylation by
exogenous hVPLA2. Again, the delayed phase activation was
abrogated by preincubation of neutrophils with LTB4DMA.
This indicates that lyso-PC induces the phosphorylation of
cPLA2 in both phases of cPLA2 activation and that the delayed
phase phosphorylation takes place via LTB4 formation and its
receptor binding.
We also measured the effects of lyso-PC, fatty acids, and
LTB4 on the change of [Ca
2]i in the perinuclear region. It has
been reported that AA (27) and LTB4 (28) can increase [Ca
2]i
in human neutrophils. We also observed that 3 M AA or 0.3 M
LTB4 rapidly enhanced [Ca
2]i in the perinuclear region to
400–600 nM. Similarly, 3 M lyso-PC spontaneously raised
[Ca2]i to 500 nM in the perinuclear region as shown in Fig. 9.
These effects on [Ca2]i are reminiscent of the effect of hVPLA2
illustrated in Fig. 5. Finally, OA up to 10 M had no effect on
[Ca2]i (data not shown).
MAP Kinases Involved in cPLA2 Phosphorylation—It has
been reported that cPLA2 is phosphorylated and activated by
different kinases in mammalian cells (29–35). In neutrophils,
cPLA2 was shown to be phosphorylated by p38 MAP kinase,
ERK1/2 MAP kinase, or both, depending on how neutrophils
are activated (20, 36). To determine how these MAP kinases
are involved in the hVPLA2-induced cPLA2 activation and
LTB4 biosynthesis in neutrophils, we first measured the effect
of hVPLA2 on p38 and ERK1/2 MAP kinase activation. Phos-
phorylation of these MAP kinases is commonly used as an
indicator of their activation. As shown in Fig. 10A, hVPLA2
caused a time-dependent phosphorylation of p38 and ERK1/2
MAP kinases. The phosphorylation of ERK1/2 exhibited a bi-
phasic pattern, peaking at 5 and 20 min, respectively, but the
delayed phase phosphorylation was more pronounced. In con-
trast, p38 phosphorylation peaked at 10 min and declined
thereafter. This suggests that both p38 and ERK1/2 MAP ki-
nases are involved in the early phase cPLA2 phosphorylation,
whereas ERK1/2 plays a predominant role in the delayed phase
cPLA2 phosphorylation. To test this notion, we measured the
effects on the time course of cPLA2 activation of specific inhib-
itors of two MAP kinase pathways: SB203580, which specifi-
cally inhibits p38 MAP kinase (37), and U0126, which specifi-
cally inhibits MEK, which is an upstream kinase of ERK1/2
(38). As shown in Fig. 10B, 30 M SB203580 significantly
inhibited the early phase cPLA2 activation with a lesser effect
on the delayed phase. 10 M U0126, however, had a much more
pronounced effect on the delayed phase cPLA2 activation while
also showing a significant effect on the early phase. Together,
FIG. 5. Time lapse changes in [Ca2]i of human neutrophils caused by exogenous hVPLA2. The fluorescence intensity of Fluo-4 near the
perinuclear region of neutrophils was monitored upon adding 10 nM hVPLA2 (arrows), and [Ca
2]i values were calculated from the intensity values
using a calibration curve (see “Experimental Procedures”). [Ca2]i changes are shown for a single representative cell in the absence (A) and
presence (B) of 0.3 M LTB4DMA (total number of cells  12).
FIG. 6. Confocal microscopic imaging of PLA2 activities in
human neutrophils. A, imaging was performed after adding 10 nM
hVPLA2 to human neutrophils that were incubated with POPS/choles-
terol/POPG/PED6/DiIC12 (107:31:20:1:1 in mol ratio) for 50 min at
37 °C. B, neutrophils were treated with 25 M AACOCF3 before the
addition of hVPLA2.
sPLA2-induced cPLA2 Activation in Neutrophils36484
these results indicate that both ERK1/2 and p38 MAP kinases
are involved in the early phase of the hVPLA2-induced cPLA2
activation in neutrophils, whereas ERK1/2 is involved primar-
ily in the delayed phase.
DISCUSSION
Neutrophils that play a key role in defense against microbial
infection release AA, LTB4, and other 5-LO products in re-
sponse to various stimuli, including bacterial peptides. Recent
studies on fMLP-induced activation of human neutrophils have
indicated that both sPLA2 and cPLA2 are involved in AA re-
lease (9), whereas cPLA2 is responsible primarily for LTB4
release (7). We showed previously that exogenously added
hVPLA2 could also elicit the release of AA and LTB4 from
unprimed human neutrophils almost as effectively as fMLP
(10). This neutrophil activation involves the direct binding of
hVPLA2 to the outer plasma membrane and the hydrolysis of
phosphatidylcholine (10) and is terminated by the internaliza-
tion and degradation of cell surface-bound hVPLA2 in a hepa-
ran sulfate proteoglycan-dependent manner (11). The present
study shows that exogenous hVPLA2 as low as 1 nM is able to
induce AA and LTB4 release from unprimed human neutro-
phils. Furthermore, the study reveals that the hVPLA2-in-
duced formation of AA and leukotrienes in human neutrophils
is a complex and dynamic process that involves cPLA2 activa-
tion by [Ca2]i increase and phosphorylation. The most salient
feature of hVPLA2-induced neutrophil activation is the two-
phase kinetics. All phenomena associated with neutrophil ac-
tivation, AA and LTB4 release, [Ca
2]i increase, and cPLA2
phosphorylation, follow similar two-phase kinetic patterns.
The time course of hVPLA2-induced OA release as well as the
effect of cPLA2 inhibition on the time course of hVPLA2-in-
duced AA release indicate that both hVPLA2 and cPLA2 con-
tribute to the early phase AA release, whereas cPLA2 is respon-
sible primarily for the delayed phase. Also, the primary sites of
action for hVPLA2 and cPLA2 are the outer plasma membrane
and the perinuclear region, respectively (see Fig. 6). Given that
the AA composition of neutrophil plasma membrane is less
than 5% (39) and that cell surface-bound hVPLA2 is readily
internalized and degraded (11), a relatively high concentration
of exogenous hVPLA2 would be necessary to liberate a signifi-
cant amount of AA from the outer plasma membrane. Indeed,
direct AA production by hVPLA2 becomes significant only when
its concentration reaches 10 nM (see Fig. 1A). Importantly, the
abrogation of LTB4 release in the presence of cPLA2 inhibitors
points to the predominant role of cPLA2 in LTB4 biosynthesis
under our experimental conditions. This in turn indicates that
the AA liberated from the outer plasma membrane of neutro-
phils by direct lipolytic action of hVPLA2 in the early phase is
not conducive to LTB4 biosynthesis by 5-LO. Thus, it would
seem that the primary role of this hVPLA2-produced AA is to
activate cPLA2. In fact, AA and other polyunsaturated fatty
acids have been shown to activate cPLA2 in neutrophils (40). In
this regard, it is noteworthy that lyso-PC is about three times
more potent than AA in inducing LTB4 biosynthesis in neutro-
phils. Also, lyso-PC should be produced in a much larger
amount than AA and polyunsaturated fatty acids from the
outer plasma membrane of neutrophils because of the abun-
dance of phosphatidylcholine. This and other results presented
herein support the notion that hVPLA2-induced activation of
neutrophils is largely mediated by lyso-PC. Lyso-PC species
containing a saturated acyl chain in the sn-1 position, including
the palmitoyl derivative employed in this study, have been
shown to activate a cell surface G protein-coupled receptor (41)
and thereby regulate a broad range of cell processes, including
increases in cAMP (42) and [Ca2]i (41) and the activation of
FIG. 7. Effects of hVPLA2 hydrolysis products and LTB4 on neutrophil activation. AA (A) and LTB4 (B) release was measured after
neutrophils were treated with each agonist (10 nM hVPLA2, 3 M AA, 3 M OA, 3 M lyso-PC, 0.3 M LTB4, or 0.3 M LTB4DMA) for 20 min. Data
represent the mean  S.E. from triplicate measurements.
FIG. 8. Time-dependent activation of neutrophil cPLA2 by ex-
ogenous lyso-PC. The effect of 3 M lyso-PC was measured in the
absence (E) and presence () of 0.3 M LTB4DMA. Experimental con-
ditions were the same as described for Fig. 4. Data represent the
mean  S.E. from triplicate measurements.
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MAP kinase (41) and protein kinase C (43). In particular, 100
M lyso-PC was shown to induce AA release and increase
[Ca2]i in rat heart myoblastic H9c2 cells (43). In our study, a
few micromolar lyso-PC effectively simulated all activities of
hVPLA2 on human neutrophils, including AA and LTB4 re-
lease, a rise in [Ca2]i, and cPLA2 phosphorylation. In partic-
ular, lyso-PC activates cPLA2 by inducing both [Ca
2]i increase
and cPLA2 phosphorylation in both early and delayed phases. A
rise in Ca2 by lyso-PC would also activate 5-LO by inducing its
translocation to the nuclear envelope (44), thereby promoting
LTB4 synthesis.
It has been shown that LTB4 can activate neutrophils by an
autocrine, positive feedback mechanism (49). Neutrophils con-
tain a cell surface G protein-coupled LTB4 receptor (50), and
the binding of LTB4 to the receptor leads to various cells acti-
vation, including a rise in [Ca2]i and the MAP kinase activa-
tion (50). It was shown previously that the agonist-induced
biosynthesis of LTB4 in neutrophils leads to cPLA2 phospho-
rylation (8). Our results clearly show that the biosynthesis of
LTB4 and its binding to the cell surface receptor play a pivotal
role in the delayed phase of hVPLA2-induced cPLA2 activation
by causing both a rise in [Ca2]i and cPLA2 phosphorylation.
Because blocking the LTB4 receptor with LTB4DMA abrogates
the [Ca2]i increase and the cPLA2 phosphorylation only in the
delayed phase, it is unlikely that LTB4 is involved in the early
phase cPLA2 activation that is mediated primarily by lyso-PC
(and polyunsaturated fatty acids). Our results also indicate
that a certain threshold concentration of LTB4 is required for
its positive feedback effect because of the relatively rapid oxi-
dative degradation of LTB4 in neutrophils. In the case of neu-
trophil activation by exogenous hVPLA2, this threshold concen-
tration of LTB4 is achieved by 10 nM hVPLA2. The threshold
LTB4 concentration was not determined directly in this study
because of difficulties involved in distinguishing between exog-
enous and endogenous LTB4.
In neutrophils, cPLA2 is phosphorylated by p38 MAP kinase,
FIG. 9. Time lapse changes in [Ca2]i of human neutrophils caused by AA (A), lyso-PC (B), and LTB4 (C). Experimental conditions were
the same as described for Fig. 5.
FIG. 10. MAP kinase activation in
hVPLA2-induced neutrophil activa-
tion. A, time lapse phosphorylation of
ERK1/2 and p38 MAP kinases in human
neutrophils treated with 10 nM hVPLA2.
B, effect of the p38 inhibitor SB203580
and MEK inhibitor U0126 on neutrophil
cPLA2 activation. Untreated neutrophils
(E) and neutrophils pretreated with 30
M SB203580 (Œ) and 10 M U0126 (‚),
respectively, were incubated with 10 nM
hVPLA2 and the cPLA2 activity measured.
Experimental conditions were the same as
described for Fig. 4. Data represent an aver-
age of duplicate measurements.
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ERK1/2, or both, depending on the nature of agonists (20).
Although the identification of the network of protein kinases
involved in hVPLA2-induced cPLA2 phosphorylation and the
site of cPLA2 phosphorylation are beyond the scope of this
investigation, our results indicate that both ERK1/2 and p38
MAP kinases are involved in the early phase cPLA2 activation,
whereas ERK1/2 is involved primarily in the delayed phase.
The direct role of ERK1/2 in cPLA2 phosphorylation in neutro-
phils has been well documented. In particular, LTB4 was
shown to activate ERK1/2 (45) but not p38 MAP kinase (46).
This is consistent with our finding that ERK1/2 is involved
mainly in the delayed phase cPLA2 phosphorylation that is
mediated by the binding of LTB4 to its receptor. It has been
shown that lyso-PC (43) and AA (and other polyunsaturated
fatty aids) (47) can activate protein kinase C. Furthermore, the
phorbol ester-induced activation of protein kinase C in neutro-
phils was shown to phosphorylate cPLA2 via ERK1/2 activation
(20). Thus, it appears that at least one signaling pathway to
cPLA2 phosphorylation in the early phase involves the protein
kinase C activation that leads to ERK1/2 activation. A previous
study reported that AA stimulated p38 phosphorylation in
neutrophils (48), Thus, AA and polyunsaturated fatty acids
released by hVPLA2 might be responsible for the p38 phospho-
rylation in the early phase of neutrophil activation by hVPLA2.
It is not clear, however, whether the activated p38 is directly or
indirectly involved in cPLA2 phosphorylation. Further studies
are necessary to sort out the effects of different protein kinases
in the activation of cPLA2 in neutrophils.
On the basis of our present and previous studies, we propose
a mechanism by which hVPLA2 induces the LTB4 biosynthesis
in human neutrophils as shown in Fig. 11. In this model,
hVPLA2 directly acts on the outer cell membranes of neutro-
phils to release fatty acids (including AA) and lysophospholip-
ids, most likely lyso-PC. Both polyunsaturated fatty acids (in-
cluding AA) and lyso-PC induce the immediate membrane
translocation of 5-LO and cPLA2 with transient Ca
2 influx.
Also, they activate cPLA2 via phosphorylation, which leads to
the liberation of AA at the perinuclear region. cPLA2 activated
by hVPLA2 products then returns to the resting state as cells
internalize hVPLA2 via heparan sulfate proteoglycan binding
and degrade them to avoid extensive lipolytic damage of the
outer plasma membrane. In the meantime, activated 5-LO
produces LTB4, which binds the cell surface LTB4 receptor in
an autocrine manner and triggers a MAP kinase cascade to
rephosphorylate and reactivate cPLA2 in the delayed phase.
This delayed phase phosphorylation of cPLA2 will then lead to
amplified and prolonged production of AA, LTB4, and other
eicosanoids.
It should be noted that this model focuses mainly on the
action of exogenous hVPLA2 on neutrophils but not on the role
of endogenous hVPLA2 in neutrophil activation. Based on the
lack of LTB4 release from human neutrophils stimulated with
fMLP and cytochalasin B, it was postulated that the endoge-
nous hVPLA2 in neutrophils is not involved in LTB4 biosynthe-
sis (7). In this report, the concentration of hVPLA2 released
from neutrophils by fMLP and cytochalasin B was estimated to
be in the low nanomolar range (7). Our study shows that even
this concentration of hVPLA2 can induce the formation of a
significant amount of LTB4 but cannot trigger the receptor-
mediated positive feedback effect because of rapid oxidative
degradation. However, the amount of hVPLA2 in human neu-
trophils seems to vary to a large extent depending on the
allergic state of donors (52),2 suggesting that higher concentra-
tions of endogenous hVPLA2 could be secreted by activated
neutrophils. Furthermore, the sPLA2 concentration in serum
and inflammatory exudates was reported be much higher (51).
In particular, mast cells and macrophages release a significant
amount of group V PLA2 in response to different stimuli.
2 It is
therefore likely that exogenous hVPLA2 is able to trigger LTB4
biosynthesis in neutrophils, either alone or in combination with
other stimuli, under pathophysiological conditions. Undoubt-
edly, further studies are necessary to address this important
question.
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